Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701529 | Journal of Thoracic Oncology | 2017 | 26 Pages |
Abstract
Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy. The phase II S0905 trial will evaluate the efficacy of the triplet regimen compared with the current standard of care, cisplatin-pemetrexed.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Anne S. MD, James MS, Ignacio I. MD, Nicholas J. MD, Gregory P. MD, Mary W. PhD, David R. MD, Karen MD,